TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients

Completed · Phase 1/Phase 2

Conditions studied: Influenza

In brief

The purpose of this study is to assess the safety and tolerability of triple combination antiviral drug (TCAD) for use in immunocompromised patients with Influenza A infection, and to gain data on the effectiveness of TCAD

Key facts

Study ID: NCT00867139
Run by: Fred Hutchinson Cancer Center
People needed: 7
Starts: 2009-03-01
Expected to finish: 2010-01-01
Last updated by the study team: 2013-08-15

Who can join

Age: 1 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

i. Inclusion criteria for randomized arms (both needed):
Age ≥7 years, male or female; AND
Influenza infection (i.e. upper respiratory tract infection)
ii. Inclusion criteria for open-label arm (at least one criteria required):
Young age (1-6 years) with any influenza severity, proven or probable influenza A (H1N1)(H274Y); OR
History of asthma; OR
Older age (≥ 7 years), with no asthma; AND
moderate to severe influenza; AND/OR
failure in randomized study monotherapy arm iii. Inclusion criteria for all subjects:
Able to provide informed consent, or for whom consent may be provided by guardian 2. Immunocompromised, as defined by one of the following:
Recent hematopoietic cell transplantation (HCT) (within 2 years, all conditioning regimens, allogeneic, autologous, syngeneic; after 2 years patients with chronic graft-versus-host disease (GVHD) requiring systemic treatment may be included) or solid organ transplantation
Patients taking at least 2 immunosuppressants
Patients undergoing combination chemotherapy within the past 3 month 3. One or more of the following:
Presence of fever at time of screening of ≥ 38.0°C (≥ 100.0°F) taken orally.
presence of at least one constitutional symptom (headache, myalgia, malaise, or fatigue) of any severity (mild, moderate, or severe),
presence of at least one respiratory symptoms (e.g. cough, or sore throat) of any severity (mild, moderate, or severe),
other flu-like symptoms, where the clinician orders a respiratory virus test including influenza A or B 4. Positive test for influenza A (if available) 5. Onset of illness no more than 5 days prior to diagnosis. 6. Females patients of child-bearing age who are capable of conception (i.e. previously have not undergone surgical sterilization) must meet the following criteria:
Have been sexually abstinent or have used contraceptive agents (oral contraceptive or other hormonal contraceptives including vaginal rings or transdermal patches, intrauterine device (IUD), or barrier methods including condoms) during the 4 weeks prior to date of screening (3 months prior to enrollment for oral/hormonal contraceptives)
Agree to be sexually abstinent or use contraceptive agents (oral contraceptive or other hormonal contraceptives including vaginal rings or transdermal patches, intrauterine device (IUD), or barrier methods including condoms) from the date of screening through 24 weeks after the last dose of study drug
Exclusion Criteria(all subjects):
Nausea that prevents taking oral medications
Use of antiviral influenza medication within 10 days(unless switched from randomized to open-label TCAD). An exception to this exclusion criterion may be made by site investigators for patients admitted after hours who receive one or two initial doses of antiviral influenza medication prior to enrollment.
Creatinine clearance (estimated by serum creatinine) less than 30 ml/min
Current clinical evidence of a recognized or suspected uncontrolled non-influenza infectious illness with onset prior to screening
Known hypersensitivity to amantadine, ribavirin, oseltamivir or zanamivir

Where it is running

Seattle Children's — Seattle, Washington, United States
Fred Hutchinson Cancer Research Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.